Women's Health: Worldwide Prescription Drug Markets

Table of Contents

CHAPTER ONE:EXECUTIVE SUMMARY

• Scope and Methodology
• Size and Growth of the Market
• Total Market Size and Forecast
• Market Outlook

CHAPTER TWO: INTRODUCTION AND OVERVIEW

• History of Women' s Health
• Female Reproductive System
• Hormone Regulation
• Market Trends
  • Women' s Health Initiative
  • Women' s Health Office Act of 2007
  • Perimenopausal Use of Contraceptives
  • Insurance Coverage for Contraceptives
  • Oral Contraceptives in Japan
  • Ovarian Cancer Test
  • Estrogen Labeling
  • Osteoporosis Drug Opportunities in Asia
  • Women' s Healthcare Access
• Demographics

CHAPTER THREE: AUTOIMMUNE DISEASES

• Overview
• Prevalence
• Chronic Fatigue Syndrome
• Treatment
• Fibromyalgia
• Treatment
• Rheumatoid Arthritis
• Treatment
• Scleroderma
• Treatment
• Sjogren' s Syndrome
• Treatment
• Systemic Lupus Erythematosus
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Ampligen
  • Actemra
  • Apilimod
  • Arcoxia
  • Cimza
  • Denosumab
  • INCBO18424
  • Interleukin (IL-1)
  • LymphoStat-B
  • Milnacipran
  • Prestara
  • Riquent
  • Veldona
• Competitive Market

CHAPTER FOUR: CANCER

• Overview
• Incidence and Mortality
• Breast Cancer
• Overview
• Treatment
• Cervical Cancer
• Overview
• Treatment
• Endometrial Cancer
• Overview
• Treatment
• Ovarian Cance
• Overview
• Treatment
• Vaginal Cancer
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Advexin
• Alvespimycin
• Arzoxifene
• Avastin
• Axtinib
• Cervarix
• Herceptin
• Karenitecin
• Pazopanib
• Pertuzumab
• Tykerb
• Yondeli
• Competitive Market

CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

• Overview
• Incidence and Prevalence
• AIDS
  • Overview
  • Treatment
  • Agenerase
  • Aptivus
  • Combivir
  • Crixivan
  • Entriva
  • Fortovase
  • Fuzeon
  • Hivid
  • Intelence
  • Invirase
  • Isentress
  • Kaletra
  • Kivexa
  • Lexiva
  • Prezista
  • Rescriptor
  • Reyataz
  • Selzentry
  • Sustiva
  • Trizivir
  • Truvada
  • Viracept
  • Viramune
• Bacterial Vaginosis
• Overview
• Treatment
• Cervical Dysplasia
• Overview
• Treatment
• Chlamydia
• Overview
• Treatment
• Condyloma Acuminata
• Overview
• Treatment
• Aldara
• Alferon N Injection
• Condylox
• Gardasil
• Genital Herpes
• Overview
• Treatment
• Zovirax
• Gonorrhea
• Overview
• Treatment
• Hepatitis
• Overview
• Treatment
• Baraclude
• Pelvic Inflammatory Disease
• Overview
• Treatment
• Syphilis
• Overview
• Treatment
• Toxic Shock Syndrome
• Overview
• Treatment
• Yeast Infections
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Ampligen
  • Bevirimat
  • Boceprevir
  • Clevudine
  • Elvitegravir
  • GS 9137
  • Hepaconda
  • IC41
  • IDX899
  • Loctero
  • R7128
  • RDEA806
  • SPO1A
  • Telaprevir
  • TMC278
  • Vicriviroc
  • VRX496
• Competitive Market

CHAPTER SIX: HORMONE-RELATED DISORDERS

• Overview
• Statistics
• Contraception
• Overview
• Treatment
• Oral Contraceptives
• Depo-Provera
• Birth Control Patch
• Vaginal Ring
• Emergency Contraception and Early Option
• Implant
• IUD
• Endometriosis
• Overview
• Treatment
• Fibroids
• Overview
• Treatment
• Infertility
• Overview
• Treatment
• Menopause
• Overview
• Treatment
• Menstrual Disorders
• Amenorrhea
• Treatment
• Dysmenorrhea
• Treatment
• Sexual Dysfunction
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Alista
• LibiGel
• NOMAC/E2
• Ophena
• Org 36286
• Competitive Market

CHAPTER SEVEN: OSTEOPOROSIS

• Overview
• Prevalence
• Prevention
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Arzoxifene
• Denosumab
• Fablyn
• MK-0822 (Odanacatib)
• Preos
• SUN E3001
• Viviant
• Competitive Market

CHAPTER EIGHT: URINARY BLADDER DISORDERS

• Overview
• Incidence and Prevalence
• Cystitis
• Overview
• Treatment
• Incontinence
• Overview
• Treatment
• Overactive Bladder
• Treatment
• Alternative Treatments
• Interstitial Cystitis
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Oxybutynin Gel
• Anturol
• PSD503
• Competitive Market

CHAPTER NINE: WORLD MARKET SUMMARY

• Overview
• Total Market Size and Forecast
• Market Analysis

CHAPTER TEN:CORPORATE PROFILES AND ANALYSIS

• Overview

APPENDIX: COMPANY DIRECTORY: MAJOR SUPPLIERS

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: The World Market Women' s Disorders 2006-2013
• Figure 1-1: The World Market Women' s Disorders 2006-2013

CHAPTER TWO: INTRODUCTION AND OVERVIEW

• Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2007
• Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2007 (Difference, in Years, between Females and Males)
• Table 2-2: World Population Growth, by Total World Population and Selected Country or Regions and Selected Characteristics
• Figure 2-2: World Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-3: United States Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-4: Five Major European Countries* Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-5: Japan Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Table 2-3: World Female Population Growth by Selected Country or Regions and Selected Age Group
• Figure 2-6: World Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-7: United States Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-8: Five Major European Countries* Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-9: Japan Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)

CHAPTER THREE: AUTOIMMUNE DISEASES

• Table 3-1: Estimated Female Prevalence of Autoimmune Diseases by Type and Geographical Distribution, Estimated 2008
• Table 3-2: The World Market for Autoimmune Disease Drugs for Women 2006-2013
• Figure 3-1: The World Market for Autoimmune Disease Drugs for Women 2006-2013
• Table 3-3: The World Market for Autoimmune Disease Drugs for Women by Disease Type 2006-2013
• Figure 3-4: The World Market for Autoimmune Disease Drugs for
• Table 3-4 Women, Revenues by Disease Type 2006-2013
• Figure 3-3: The World Market for Autoimmune Disease Drugs for
• Figure 3-4: The World Market for Autoimmune Disease Drugs for Women, Market Share by Disease Type 2013
• Table 3-8: The World Market for Autoimmune Disease Drugs for
• Women Market Analysis by Region/Country, 2008
• Figure 3-5: The World Market for Autoimmune Disease Drugs for Women Market Analysis by Region/Country, 2008
• Table 3-5 Select Products in Development for Chronic Fatigue Syndrome 2008
• Table 3-6: Select Products in Development for Fibromyalgia 2008
• Table 3-7: Select Products in Development for Rheumatoid Arthritis 2008
• Table 3-8: Products in Development for Sjogren' s Syndrome, 2008
• Table 3-9: Products in Development for Systemic Lupus Erythematosus 2008
• Table 3-6: The World Market for Autoimmune Disease Drugs for Women Revenues and Market Share by Supplier 2008
• Figure 3-10: The World Market for Autoimmune Disease Drugs for Women Market Share by Leading Supplier 2008

CHAPTER FOUR: CANCER

• Table 4-1: Estimated Incidence of Female Cancers and Mortality by Type and Geographical Distribution, Estimated 2008
• Table 4-2: The World Market for Cancer Drugs for Women 2006-2013
• Figure 4-1: The World Market for Cancer Drugs for Women 2006-2013
• Table 4-3: The World Market for Cancer Drugs for Women by Disease Type 2006-2013
• Figure 4-2: The World Market for Cancer Drugs for Women, Revenues by Cancer Type 2006-2013
• Figure 4-3: The World Market for Cancer Drugs for Women, Market Share by Cancer Type 2008
• Figure 4-4: The World Market for Cancer Drugs for Women, Market Share by Cancer Type 2013
• Table 4-4: The World Market for Cancer Drugs for Women Market Analysis by Region/Country, 2008
• Figure 4-5: The World Market for Cancer Drugs for Women Market Analysis by Region/Country, 2008
• Table 4-5: Select Products in Development for Breast Cancer 2008
• Table 4-6: Select Products in Development for Cervical Cancer 2008
• Table 4-7: Select Products in Development for Endometrial Cancer 2008
• Table 4-8: Select Products in Development for Ovarian Cancer 2008
• Table 4-9: Select Products in Development for Vaginal Cancer, 2008
• Table 4-6: The World Market for Cancer Drugs for Women Revenues and Market Share by Supplier 2008
• Figure 4-10: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2008

CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

• Table 5-1: Estimated Female Incidence and Prevalence Gynecological and Sexually Transmitted Diseases by Type and Geographical Distribution, 2007/2008
• Table 5-2: Gynecological and Sexually Transmitted Diseases Related Epidemiologic Data, Five Year Average 2007/2008 Average
• Table 5-3: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women 2006-2013
• Figure 5-1: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women 2006-2013
• Table 5-4: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women by Disease Type 2006-2013
• Figure 5-2: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women, Revenues by Disease Type 2006-2013
• Figure 5-3: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women, Market Share by Disease Type 2008
• Figure 5-4: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women, Market Share by Disease Type 2013
• Table 5-5: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Analysis by Region/Country, 2008
• Figure 5-5: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Analysis by Region/Country, 2008
• Table 5-6: Select Products in Development for AIDS/HIV 2008
• Table 5-7: Select Products in Development for Cervical Dysplagia 2008
• Table 5-8: Select Products in Development for Condyloma Acumenta 2008
• Table 5-9: Select Products in Development for Genital Herpes 2008
• Table 5-10: Select Products in Development for Hepatitis, 2008
• Table 5-6: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Revenues and Market Share by Supplier 2008
• Figure 5-11: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Share by Leading Supplier 2008

CHAPTER SIX: HORMONE-RELATED DISORDERS

• Table 6-1: Estimated World and U.S. Female Incidence and Prevalence of Hormone-Related Disorders and Indications by Type, Five Year Average 2007/2008
• Table 6-2: Estimated World and U.S. Contraceptive Use by Method, Five Year Average 2007/2008
• Table 6-3: Selected Oral Contraceptives Available 2007/2008
• Table 6-4: Selected Hormone Replacement Therapies
• Table 6-5: The World Market for Hormone-related Disorders for Women, 2006-2013
• Figure 6-1: The World Market for Hormone-related Disorders for Women 2006-2013
• Table 6-6: The World Market for Hormone-related Disorders for Women by Disorder Type 2006-2013
• Figure 6-2: The World Market for Hormone-related Disorders for Women, Revenues by Disorder Type 2006-2013
• Figure 6-3: The World Market for Hormone-related Disorders for Women, Market Share by Disorder Type 2008
• Figure 6-4: The World Market for Hormone-related Disorders for Women, Market Share by Disorder Type 2013
• Table 6-7: The World Market for Hormone-related Disorders for Women Market Analysis by Region/Country, 2008
• Figure 6-5: The World Market for Hormone-related Disorders for Women Market Analysis by Region/Country, 2008
• Table 6-8: Select Products in Development for Oral Contraceptives 2008
• Table 6-9: Select Products in Development for Endometriosis 2008
• Table 6-10: Select Products in Development for Infertility 2008
• Table 6-11: Select Products in Development for Menopause 2008
• Table 6-12: Select Products in Development for Menstrual Disorders 2008
• Table 6-13: Select Products in Development for Sexual Dysfunction 2008
• Table 6-14: The World Market for Hormone-related Disorders for Women Revenues and Market Share by Supplier 2008
• Figure 6-6: The World Market for Hormone-related Disorders for Women Market Share by Leading Supplier 2008

CHAPTER SEVEN: OSTEOPOROSIS

• Table 7-1: Estimated Female Prevalence of Osteoporosis by Type and Geographical Distribution, Average 2007/2008
• Table 7-2: The World Market for Osteoporosis Treatments for Women 2006-2013
• Figure 7-1: The World Market for Osteoporosis Treatments for Women 2006-2013
• Table 7-3: The World Market for Osteoporosis Treatments for Women Market Analysis by Region/Country, 2008
• Figure 7-2: The World Market for Osteoporosis Treatments for Women Market Analysis by Region/Country, 2008
• Table 7-4: Select Products in Development for Osteoporosis Drugs 2008
• Table 7-5: The World Market for Osteoporosis Treatments for Women Revenues and Market Share by Supplier 2008
• Figure 7-3: The World Market for Osteoporosis Treatments for Women Market Share by Leading Supplier 2008

CHAPTER EIGHT: URINARY BLADDER DISORDERS

• Table 8-1: Estimated Female Incidence and Prevalence of Urinary Bladder Disorders by Type and Geographical Distribution, Average 2007/2008
• Table 8-2: Medications That Can Affect Urination
• Table 8-3: The World Market for Urinary Bladder Disorders for Women 2006-2013
• Figure 8-1: The World Market for Urinary Bladder Disorders for Women 2006-2013
• Table 8-4: The World Market for Urinary Bladder Disorders for Women by Disease Type 2006-2013
• Figure 8-2: The World Market for Urinary Bladder Disorders for Women, Revenues by Disease Type 2006-2013
• Figure 8-3: The World Market for Urinary Bladder Disorders for Women, Market Share by Disease Type 2008
• Figure 8-4: The World Market for Urinary Bladder Disorders for Women, Market Share by Disease Type 2013
• Table 8-5: The World Market for Urinary Bladder Disorders for Women Market Analysis by Region/Country, 2008
• Figure 8-5: The World Market for Urinary Bladder Disorders for Women Market Analysis by Region/Country, 2008
• Table 8-6: Select Products in Development for Urinary Disorders 2008
• Table 8-7: The World Market for Urinary Bladder Disorders for Women Revenues and Market Share by Supplier 2008
• Figure 8-6: The World Market for Urinary Bladder Disorders for Women Market Share by Leading Supplier 2008

CHAPTER NINE: WORLD MARKET SUMMARY

• Table 9-1: The World Market for Women' s Disorders, Revenues by Product Segment 2006-2013
• Figure 9-1: The World Market for Women' s Disorders, Revenues by Product Segment 2006-2013

CHAPTER TEN: CORPORATE PROFILES AND ANALYSIS

• Table 10-1: The World Market for Women' s Disorders, Revenues and Market Share by Supplier 2008
• Figure 10-2: The World Market for Women' s Disorders, Top Ten Suppliers by Percent, 2008